These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 16344532)
1. Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. Martignoni E; Cosentino M; Ferrari M; Porta G; Mattarucchi E; Marino F; Lecchini S; Nappi G Neurology; 2005 Dec; 65(11):1820-2. PubMed ID: 16344532 [TBL] [Abstract][Full Text] [Related]
2. Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients. Ferrari M; Martignoni E; Blandini F; Riboldazzi G; Bono G; Marino F; Cosentino M Eur J Clin Pharmacol; 2012 Nov; 68(11):1493-9. PubMed ID: 22527346 [TBL] [Abstract][Full Text] [Related]
3. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]. Arnold G; Kupsch A Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007 [TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of COMT inhibitors. Brooks DJ Neurology; 2004 Jan; 62(1 Suppl 1):S39-46. PubMed ID: 14718679 [TBL] [Abstract][Full Text] [Related]
6. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. Kaakkola S Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464 [TBL] [Abstract][Full Text] [Related]
7. Entacapone-induced hepatotoxicity and hepatic dysfunction. Fisher A; Croft-Baker J; Davis M; Purcell P; McLean AJ Mov Disord; 2002 Nov; 17(6):1362-5; discussion 1397-1400. PubMed ID: 12465084 [TBL] [Abstract][Full Text] [Related]
8. Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors. Männistö PT Adv Pharmacol; 1998; 42():324-8. PubMed ID: 9327906 [No Abstract] [Full Text] [Related]